NCT05161104

Brief Summary

The heart, one of the most important organs for oxygen supply and consumption, is frequently involved in sepsis, i.e. septic cardiomyopathy, also known as septic myocardial suppression. The occurrence of septic myocardial suppression increases mortality in septic patients. Recent studies have found that left ventricular hyperdynamic state (EF \> 70%) is associated with intra-ICU mortality in septic patients, possibly because it reflects unresolved vascular paralysis from sepsis . For septic myocardial suppression, there is still a lack of uniform criteria for diagnosis, but it is well established that the cardiac ultrasound phenotype of septic myocardial suppression can be left ventricular systolic insufficiency (LVSD), left ventricular diastolic insufficiency (LVDD), right ventricular insufficiency (RVD), diffuse ventricular insufficiency, and mixed ventricular insufficiency. According to incomplete statistics, the prevalence of LVSD ranges from 12 to 60%, the prevalence of LVDD is higher, 20% to 79%, and the prevalence of RVD varies from 30% to 55%. However, based on the current understanding of septic myocardial suppression, the relationship between each staging and its prognosis is unclear, and echocardiography can rapidly identify septic myocardial suppression and guide the classification of septic myocardial suppression to further optimize the diagnosis and treatment process of sepsis, especially to avoid over-resuscitation during fluid resuscitation and perform reverse resuscitation in a timely manner to improve patient prognosis and reduce hospitalization time. The aim of this study is to classify and evaluate the prognosis of patients with different septic cardiac ultrasound phenotypes in multiple centers across China by measuring the right and left heart systolic and diastolic indices by echocardiography, recording the baseline conditions and clinical indices of patients, and combining them with the prognosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 23, 2021

Completed
Same day until next milestone

Study Start

First participant enrolled

November 23, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

December 16, 2021

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 23, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

November 23, 2025

Completed
Last Updated

December 16, 2021

Status Verified

November 1, 2021

Enrollment Period

3 years

First QC Date

November 23, 2021

Last Update Submit

December 6, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • in-hospital mortality

    Number of patient deaths divided by the total number

    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

  • 28-day mortality

    Number of patient deaths within 28 days divided by the total number

    From patient admission to day 28

Secondary Outcomes (2)

  • length of stay in the ICU

    days from patient transfer to ICU to transfer out,an average of 1 week

  • number of days of mechanical ventilation

    Days the patient was mechanically ventilated until the cessation of mechanical ventilation,an average of 1 week

Study Arms (6)

left ventricular systolic dysfunction(LVSD)

left ventricular diastolic dysfunction(LVDD)

right ventricular dysfunction(RVD)

diffuse ventricular dysfunction

hyperdynamic state left ventricular function

Normal

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with sepsis or septic shock who conform to Sepsis 3.0 diagnostic criteria and were more than or equal to 18 years of age who were admitted to each center were included. Sepsis was defined as an increase of ≥2 points from baseline in sequential organ failure assessment (SOFA) score due to infection; septic shock was defined as persistent hypotension on top of sepsis, requiring vasoactive drugs to maintain a mean arterial pressure(MAP) ≥65 mmHg and a blood lactate level \>2 mmol/L despite adequate fluid resuscitation.

You may qualify if:

  • \- All patients with sepsis or septic shock who conform to Sepsis 3.0 diagnostic criteria

You may not qualify if:

  • Patients with preexisting chronic heart disease such as cardiomyopathy, chronic pulmonary heart disease, severe cardiac valve disease, coronary heart disease, congenital heart disease, pericardial disease, etc. and with cardiac function ≥ grade III (NYHA classification) prior to sepsis.
  • End-stage malignancies.
  • Severe trauma.
  • Pregnancy.
  • Patients for whom transthoracic echocardiography data are not available.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fujian Provincial Hospital

Fuzhou, Fujian, 350000, China

Location

Related Publications (1)

  • Zhang H, Wang X, Yin W, Zhang H, Liu L, Pan P, Zhu Y, Huang W, Xing Z, Yao B, Wang C, Lin T, Yu R, Shang X. A multicenter prospective cohort study of cardiac ultrasound phenotypes in patients with sepsis: Study protocol for a multicenter prospective cohort trial. Front Med (Lausanne). 2022 Jul 27;9:938536. doi: 10.3389/fmed.2022.938536. eCollection 2022.

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

November 23, 2021

First Posted

December 16, 2021

Study Start

November 23, 2021

Primary Completion

November 23, 2024

Study Completion

November 23, 2025

Last Updated

December 16, 2021

Record last verified: 2021-11

Locations